Viracor Eurofins Clinical Diagnostics, Lee's Summit, MO 64086, USA.
Viracor Eurofins Clinical Diagnostics, Lee's Summit, MO 64086, USA.
J Clin Virol. 2020 Aug;129:104439. doi: 10.1016/j.jcv.2020.104439. Epub 2020 May 19.
Real-time reverse transcriptase polymerase chain reaction (rRTPCR) has been the main method for diagnosis of SARS-CoV-2 infection in the early stages of the COVID-19 pandemic. De-identified results from upper and lower respiratory samples submitted to a reference laboratory demonstrated a positivity rate of 14.9 % (4428 of 29,713 samples tested). Distribution of results by birth year cohort and specimen type suggested general consistency in mean, median and peak values but higher positivity rates in individuals born from 1964 to 1974. Female patients had a significantly lower positivity rate (P < 0.0001), although similar load mean and median values, compared to males. Overall, 15.3 % (676 of 4428 positive results) of positive results had viral loads greater than 8 log10 copies/mL, with occasional samples exceeding 10 log10 copies/mL. These results support quantitative assessment of SARS-CoV-2 viral load in patient testing and efforts to control viral transmission.
实时逆转录聚合酶链反应(rRT-PCR)一直是 COVID-19 大流行早期诊断 SARS-CoV-2 感染的主要方法。提交给参考实验室的上呼吸道和下呼吸道样本的去识别结果显示阳性率为 14.9%(29713 个测试样本中的 4428 个)。按出生年份队列和样本类型分布的结果表明,平均值、中位数和峰值总体上一致,但在 1964 年至 1974 年出生的个体中阳性率更高。与男性相比,女性患者的阳性率显著较低(P<0.0001),但平均和中位数病毒载量相似。总体而言,4428 个阳性结果中有 15.3%(676 个)的病毒载量大于 8 log10 拷贝/mL,偶尔有样本超过 10 log10 拷贝/mL。这些结果支持对患者检测中的 SARS-CoV-2 病毒载量进行定量评估,并努力控制病毒传播。